Applied StemCell, Inc. enters strategic partnership with Charles

Applied StemCell, Inc. enters strategic partnership with Charles River Laboratories

Menlo Park, CA- Mar. 18, 2013—Applied StemCell, Inc. (ASC) announced today it has signed a strategic agreement with Charles River Laboratories International, Inc. (NYSE: CRL) for the distribution of ASC’s genetically modified TARGATT™ mouse. With this agreement, Charles River becomes the worldwide distributor of the TARGATT™ (FVB) mouse. ASC’s IP based technology, TARGATT™ allows a gene of interest to be stably integrated into  a well-characterized, transcriptionally-active locus in the mouse genome with guaranteed transgene expression. With the TARGATT™ (FVB) mouse and transgenic kit (available from ASC), researchers are able to generate a site-specific knock-in mouse in as fast as 3 months.

Ruhong Jiang, President and CEO of Applied StemCell, Inc. said, “We are extremely pleased that ASC and Charles River have entered into a strategic partnership. This expands our accessibility to the research market and builds a new platform to deliver innovative gene modification solutions. We will continuously work together to seek new business opportunities.”